在符合医疗保险资格的队列中按乳腺癌风险水平使用雷洛昔芬和他莫昔芬的情况
研究评估了前列腺、肺、结直肠和卵巢癌筛查试验中老年女性按5年乳腺癌风险水平使用雷洛昔芬和他莫昔芬的情况。数据显示,2013年雷洛昔芬近期使用率随风险升高而增加(<1.66%组1.8%,1.66-3.0%组2.5%,≥3%组4.0%,趋势P<.0001),但总体使用率低,且2010-2014年间使用显著下降;他莫昔芬使用率极低(三组分别为0.36%、0.45%、0.85%,趋势P=.009)。
要点
- 雷洛昔芬近期使用率随5年乳腺癌风险升高而增加,但总体使用率低(最高4.0%)。
- 他莫昔芬使用率极低,三组风险水平分别为0.36%、0.45%、0.85%。
- 2010-2014年间雷洛昔芬使用显著下降,包括5年风险≥3%的女性。
核心结论
- 雷洛昔芬总体使用率低,但随乳腺癌风险适度增加,且2010-2014年间使用下降;他莫昔芬使用率极低。
研究设计与样本
- 研究评估了前列腺、肺、结直肠和卵巢癌筛查试验中入组的女性,数据来源为2013年邮寄的药物使用问卷和2010-2014年关联的Medicare Part D理赔文件。
- 共22,235名女性完成药物使用问卷,其中13,640名(61%)有Part D关联数据。
- 2013年45%的女性为65-74岁,55%为75-84岁。
- 5年内乳腺癌风险采用改良Gail模型和自报乳腺癌危险因素评估,合并症通过问卷评估。
主要发现
- 来自药物使用问卷,过去一个月雷洛昔芬使用率在5年内乳腺癌风险<1.66%、1.66-3.0%、≥3%的女性中分别为1.8%、2.5%、4.0%(趋势P<.0001)。
- 来自Part D,有覆盖的女性中任何使用雷洛昔芬的比率在三个5年内乳腺癌风险类别中分别为3.3%、4.0%、6.6%(趋势P<.0001);有骨质疏松和无骨质疏松的女性使用率分别为7.4%和3.3%。
- 雷洛昔芬使用从2010-2014年显著下降, specifically从2012-2014年,在全部女性和5年内乳腺癌风险≥3%的女性中均如此。
- 来自Part D,他莫昔芬使用率在三个5年内乳腺癌风险类别中分别为0.36%、0.45%、0.85%(趋势P=.009)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Raloxifene and tamoxifen are Food and Drug Administration-approved for breast cancer risk reduction; in 2013, the US Preventive Services Task Force recommended these drugs for breast cancer risk reduction in high-risk women. Information on the use of raloxifene and tamoxifen for breast cancer risk reduction in the general population indicates that the risk is believed to be low; however, there is little literature. OBJECTIVE: The purpose of this study was to assess the use of breast cancer risk reduction medications by breast cancer risk level in an older cohort of women. STUDY DESIGN: Women who were enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were assessed for the use of raloxifene, tamoxifen, and other medications. The data sources for use of the drugs were a mailed medication use questionnaire in 2013 and linked Medicare Part D claims files from 2010-2014. Estimated breast cancer risk within 5 years was assessed with the use of the modified Gail model and self-reported breast cancer risk factors; comorbidities were assessed through a questionnaire. RESULTS: A total of 22,235 women completed the medication use questionnaire; of these, 13,640 women (61%) had linked Part D data. In 2013, 45% of the women were 65-74 years old, and 55% of the women were 75-84 years old. From the medication use questionnaire, raloxifene use (past month) was 1.8%, 2.5%, and 4.0% for women with breast cancer risk within 5 years of <1.66%, 1.66-3.0%, and ≥3%, respectively (probability value trend, <.0001). From Part D, for any use during the period among women with coverage, raloxifene rates were 3.3%, 4.0%, and 6.6% for the 3 categories for breast cancer risk within 5 years (probability value trend, <.0001); use was 7.4% and 3.3% in women with and without osteoporosis, respectively. Raloxifene use significantly decreased from 2010-2014, and specifically from 2012-2014, both for all women and for women with breast cancer risk within 5 years of ≥3%. Tamoxifen use from Part D was 0.36%, 0.45%, and 0.85% for the 3 categories for breast cancer risk within 5 years (probability value trend, .009). CONCLUSION: Raloxifene use was low overall but increased modestly with breast cancer risk, and usage decreased from 2010-2014. Tamoxifen use was very low.
引用
- Pinsky PF, Miller E, Heckman-Stoddard B, et al. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort. Am J Obstet Gynecol. 2018. PMID: 29630889. doi:10.1016/j.ajog.2018.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。